Samsung Biologics and Pfizer have struck a “long-term” deal worth more than $400m that will see the Korean company manufacture multiple biosimilars for Pfizer.
Samsung Biologics Strikes $400m+ Biosimilars Supply Deal With Pfizer
‘Long Term’ Arrangement Covers ‘Large-Scale Manufacturing’ For Pfizer Portfolio
Samsung Biologics has struck a deal worth over $400m to manufacture multiple biosimilars for Pfizer.
